{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-056224","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.966143+00:00","generated_at":"2026-06-01T01:42:38.269557+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Unicycive Therapeutics doubles authorized common stock to 400M shares","bullets":["Stockholders approved increase from 200M to 400M shares on June 20, 2024.","Certificate of Amendment filed with Delaware on June 21, 2024, effective immediately.","No specific use of the additional shares or dilution impact disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-056224","json":"https://secwatch.observer/filing/0001213900-24-056224.json","markdown":"https://secwatch.observer/filing/0001213900-24-056224.md","text":"https://secwatch.observer/filing/0001213900-24-056224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024056224/0001213900-24-056224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390024056224/ea0208510-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:42:38.269557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}